• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Chemical Engineering
  • All Events
  • Seminars
  • Contact Us
  • Giving
  • About
    • Mission, Vision and Values
    • ChE Advisory Board
    • Diversity, Equity and Inclusion
    • Reporting Concerns and Misconduct
    • Faculty Search
    • Contact Us
  • News
  • Research
    • Research Areas
      • Biomolecular Engineering
      • Catalysis and Reaction
      • Cellular Engineering
      • Computing and Simulation
      • Materials
      • Microfabricated Systems
      • Nanotechnology
      • Polymers and Complex Fluids
      • Sustainable Energy
    • Facilities
    • Research Programs for Undergraduates
    • Partners in Industry
  • People
    • Administration
    • All Faculty
    • Core Faculty
    • Doctoral Students
    • Master’s Students
    • Postdoctoral Research Fellows
    • Staff
  • Graduate
    • Program
      • Graduate Degree Requirements
      • SUGS
      • Additional Options
      • Doctoral Candidacy Exam
      • Thesis Proposal Exam
      • Doctoral Committee
    • Prospective Students
      • Admissions Requirements
      • Admissions Timeline
      • TOEFL and GRE
      • Financial Support
      • Recruitment
      • Frequently Asked Questions
    • Current Students
      • Diversity, Equity and Inclusion
      • GSI Positions
      • Curricular Practical Training for F-1 Students
      • ChE Graduate Student Committee
    • Graduate Contacts
    • Why Michigan?
    • Housing
  • Undergraduate
    • Program
      • Mission
      • Incorporating Outreach
      • Program Improvement
      • Enrollment Data
    • Join Chemical Engineering
    • Degree Requirements
      • Intellectual Breadth
      • Courses & Course Profiles
    • Minors, Concentrations and Specialized Studies
    • Dual and Combined Degrees
    • Masters and SUGS Programs
    • Jobs and Research
      • Cooperative Education
    • Student Resources
      • Funding for Travel
      • Scholarships
      • Frequently Asked Questions
    • Student Groups
      • Funding for Groups
    • Undergraduate Contacts
  • Alumni
    • Stay Connected
    • Get Involved
    • Giving
    • Recruit Talent
    • Alumni Profiles
    • All Events
    • Seminars
    • Contact Us
    • Giving

$2.38M to test nano-engineered brain cancer treatment in mice

A protein that crosses the blood-brain barrier carries a drug that kills tumor cells and another that activates the immune system.

Written by: Michigan Engineering

June 15, 2022

Colin Greineder wearing his work jacketColin Greineder
Assistant Professor of Emergency Medicine
Portrait of Pedro Lowenstein smiling. He's wearinga. black suit white a black tie and a white shirt.Pedro Lowenstein
Richard Schneider Collegiate Professor and a professor of neurosurgery
Portrait of Mario Castro who has black hair and is wearing a black outfit with a few necklaces.Maria Castro
R. C. Schneider Collegiate Professor and a professor of neurosurgery
Joerg Lahann smiling wearing a grey suit and white shirtJoerg Lahann
Wolfgang Pauli Collegiate Professor of Engineering, Director of the Biointerfaces Institute

U-M EXPERTS:

A new nanomedicine that crosses the blood-brain barrier, engages the immune system and kills cancer cells may offer hope for treating the most aggressive form of brain cancer, glioblastoma. With $2.38 million in funding from the National Institutes of Health, the medicine will soon be tested in mice at the University of Michigan.

Led by a nano-engineer and neuro-oncology researchers at U-M, the study is the first to test the two drugs together, packaged so that they can be delivered through the bloodstream rather than a hole in the skull. It builds on previous success eliminating cancer in seven out of eight mice by packaging just the immune drug in the protein that crosses the blood-brain barrier so that it could be delivered intravenously. The 5-year survival rate for glioblastoma in humans is about 5%. 

“The standard of care for glioblastoma is surgery and radiation, and the median survival hasn’t improved for several decades. A systemically delivered nanomedicine that can prolong survival and prevent recurrence is the dream,” said Maria Castro, the R. C. Schneider Collegiate Professor and a professor of neurosurgery. Her team leads the mouse studies in collaboration with Pedro Lowenstein, the Richard Schneider Collegiate Professor and a professor of neurosurgery.

As the team tests out the nanoparticles timed to release the immune drug followed by a tumor-killing drug, developed and produced by Lahann’s group, one of the key questions is how well the drugs cooperate.

A diagram of how the nanomedicine is made
The diagram shows how the nanoparticles are made. Each syringe contains one of the drugs suspended in a protein solution, which come together at the end of the needle. There, a positive voltage causes the solution to rapidly accelerate, the liquid evaporating in flight on the way to the grounded collection surface. This produces solid, two-compartment nanoparticles. Credit: Ava Mauser, Lahann Lab, University of Michigan.

“Are they working much better than either drug alone? That’s what we’re hoping for. Or is it just a small improvement—or are they actually competing with each other and making the treatment worse or increasing the side effects?” said Joerg Lahann, the Wolfgang Pauli Collegiate Professor of Engineering and project lead.

The advanced nanomedicines are delivered intravenously and combined with radiation therapy, as they would be in a future clinical trial. 

To get the nanomedicine from the bloodstream to the brain, Lahann’s team packages the drugs in a protein called human serum albumin, which is present in blood and can cross the blood-brain barrier. Once there, the drugs must wake up the immune system to prevent recurrence and death, which frequently follow conventional treatments like surgery, radiation and chemotherapy. 

Tumors grow and regrow because cancer cells have ways of suppressing the immune system. The 2020 study and the new grant use a drug that blocks STAT3, a signaling molecule that cancer cells use to tell immune cells not to attack them. This gave the immune system of the mice the ability to identify the cancer cells as targets for destruction.

In a study just out in May, the team used a drug that blocks CXCR4, an immune receptor that receives orders to send killer T-cells away. Blocking CXCR4 helps keep T-cells in the brain, where they do their work of killing brain cancer cells. Three out of five mice survived long-term, and all of those survivors cleared new tumors during the recurrence challenge. While the new grant won’t use this drug, the team is interested in a future study exploring whether two immune approaches together might be more effective.

“Tumors have a lot of variation, so we need to attack them from many directions,” said Lowenstein.

After initial testing of the new two-compartment nanomedicine in lab-grown cell cultures that mimic human tumors and their surroundings, the team will begin testing in mice as the next step toward clinical trials in humans. They will find out how much of the nanomedicine makes it into the brain, how well it fights the cancer, how well it leaves the body and what the side effects are like. The previous studies suggest that the nanoparticles home in on tumor cells, infiltrating them more often than healthy cells, and one of the goals for this one is to better understand how that works.

The two-compartment nanoparticles as seen with fluorescence microscopy.
The two-compartment nanoparticles as seen with structured illumination microscopy. The green compartment contains the immune drug while the red compartment brings the tumor-killer. Credit: Ava Mauser and Nahal Habibi, Lahann Lab, University of Michigan.

“For nanomedicines to advance into clinical trials as experimental treatments for glioblastoma, we must understand the mechanisms by which they accumulate in tumor and other tissues,” said Colin Greineder, an assistant professor of emergency medicine at U-M, who will lead studies of how the nanomedicine distributes in the body.

Lahann is also the director of the Biointerfaces Institute at U-M. Castro and Lowenstein are also professors of cell and developmental biology.

Explore: Biomolecular Engineering Chemical Engineering Health Nanotechnology Polymers and Complex Fluids Joerg Lahann

Footer

  • All Events
  • Seminars
  • Contact Us
  • Giving
  • Michigan Engineering
  • Strategic Vision
  • Graduate and Professional
  • Undergraduate
  • Michigan Engineering Research News

  • Facebook
  • LinkedIn
  • Twitter

© 2023 The Regents of the University of Michigan Ann Arbor, MI 48109 USA Privacy Policy | Non-Discrimination Policy | Campus Safety